{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreighgqerbae2cmyy6a3coab5ysgjjakwbqldinni5laav46xibddq4",
    "uri": "at://did:plc:3ueatpf6zh5nibd6nd3pao4o/app.bsky.feed.post/3mpnvogeljka2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiay4j6mig6qur2tt2qz24wtcc4wfxxmjjyq2inmmq2thkh6om7rha"
    },
    "mimeType": "image/jpeg",
    "size": 1220636
  },
  "path": "/older-americans-left-out-of-costly-glp-1-craze-expected-to-flock-to-new-program/",
  "publishedAt": "2026-07-01T15:50:15.000Z",
  "site": "https://athletechnews.com",
  "tags": [
    "Fitness",
    "Nutrition",
    "Uncategorized",
    "FDA",
    "GLP-1",
    "older adults",
    "weight loss drugs"
  ],
  "textContent": "The U.S. Centers for Medicare & Medicaid Services' 18-month trial program will offer for the first time Novo Nordisk's Wegovy and Eli Lilly's Foundayo and Zepbound as a weight-loss treatment alone.",
  "title": "Older Americans Left Out of Costly GLP-1 Craze Expected to Flock to New Program"
}